XNR

N-(3-{[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl}-5-fluoro-2-methylphenyl)-4-fluorobenzene-1-sulfonamide

Created:	2022-11-30
Last modified:	2023-03-01

Find Related PDB Entry
1 entries where XNR is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	65
Chiral Atom Count	1
Bond Count	68
Aromatic Bond Count	12

2D diagram of XNR

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	N-(3-{[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl}-5-fluoro-2-methylphenyl)-4-fluorobenzene-1-sulfonamide
Systematic Name (OpenEye OEToolkits)	~{N}-[3-[[(3~{S})-4-cyclopentylcarbonyl-3-methyl-piperazin-1-yl]methyl]-5-fluoranyl-2-methyl-phenyl]-4-fluoranyl-benzenesulfonamide
Formula	C₂₅ H₃₁ F₂ N₃ O₃ S
Molecular Weight	491.594
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	Fc1ccc(cc1)S(=O)(=O)Nc1cc(F)cc(CN2CC(C)N(CC2)C(=O)C2CCCC2)c1C
SMILES	CACTVS	3.385	C[CH]1CN(CCN1C(=O)C2CCCC2)Cc3cc(F)cc(N[S](=O)(=O)c4ccc(F)cc4)c3C
SMILES	OpenEye OEToolkits	2.0.7	Cc1c(cc(cc1NS(=O)(=O)c2ccc(cc2)F)F)CN3CCN(C(C3)C)C(=O)C4CCCC4
Canonical SMILES	CACTVS	3.385	C[C@H]1CN(CCN1C(=O)C2CCCC2)Cc3cc(F)cc(N[S](=O)(=O)c4ccc(F)cc4)c3C
Canonical SMILES	OpenEye OEToolkits	2.0.7	Cc1c(cc(cc1NS(=O)(=O)c2ccc(cc2)F)F)CN3CCN([C@H](C3)C)C(=O)C4CCCC4
InChI	InChI	1.06	InChI=1S/C25H31F2N3O3S/c1-17-15-29(11-12-30(17)25(31)19-5-3-4-6-19)16-20-13-22(27)14-24(18(20)2)28-34(32,33)23-9-7-21(26)8-10-23/h7-10,13-14,17,19,28H,3-6,11-12,15-16H2,1-2H3/t17-/m0/s1
InChIKey	InChI	1.06	BARSGQAUTAPATR-KRWDZBQOSA-N

Related Resource References

Resource Name	Reference
PubChem	166625100

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.